Insel TR. Rethinking schizophrenia. Nature 2010;468:187–93.
McCleery A, Nuechterlein KH. Cognitive impairment in psychotic illness: prevalence, profile of impairment, developmental course, and treatment considerations. Dialogues Clin Neurosci. 2019;21:239–48.
Dickson H, Laurens KR, Cullen AE, Hodgins S. Meta-analyses of cognitive and motor function in youth aged 16 years and younger who subsequently develop schizophrenia. Psychol Med. 2012;42:743–55.
Aas M, Dazzan P, Mondelli V, Melle I, Murray RM, Pariante CM. A systematic review of cognitive function in first-episode psychosis, including a discussion on childhood trauma, stress, and inflammation. Front Psychiatry. 2014;4:182.
MacCabe JH, Lambe MP, Cnattingius S, Torrång A, Björk C, Sham PC, et al. Scholastic achievement at age 16 and risk of schizophrenia and other psychoses: a national cohort study. Psychol Med. 2008;38:1133–40.
Flaaten CB, Melle I, Bjella T, Engen MJ, Åsbø G, Wold KF, et al. Domain-specific cognitive course in schizophrenia: Group- and individual-level changes over 10 years. Schizophr Res Cogn. 2022;30:100263.
Samamé C, Cattaneo BL, Richaud MC, Strejilevich S, Aprahamian I. The long-term course of cognition in bipolar disorder: a systematic review and meta-analysis of patient-control differences in test-score changes. Psychol Med. 2022;52:217–28.
Bowie CR, Harvey PD. Cognitive deficits and functional outcome in schizophrenia. Neuropsychiatr Dis Treat. 2006;2:531–6.
Gitlin MJ, Miklowitz DJ. The difficult lives of individuals with bipolar disorder: A review of functional outcomes and their implications for treatment. J Affect Disord. 2017;209:147–54.
Nuechterlein KH, Subotnik KL, Green MF, Ventura J, Asarnow RF, Gitlin MJ, et al. Neurocognitive Predictors of Work Outcome in Recent-Onset Schizophrenia. Schizophr Bull. 2011;37:S33–S40.
Cowman M, Holleran L, Lonergan E, O’Connor K, Birchwood M, Donohoe G. Cognitive Predictors of Social and Occupational Functioning in Early Psychosis: A Systematic Review and Meta-analysis of Cross-Sectional and Longitudinal Data. Schizophr Bull. 2021;47:1243–53.
Van Rheenen TE, Lewandowski KE, Tan EJ, Ospina LH, Ongur D, Neill E, et al. Characterizing cognitive heterogeneity on the schizophrenia-bipolar disorder spectrum. Psychol Med. 2017;47:1848–64.
Vaskinn A, Haatveit B, Melle I, Andreassen OA, Ueland T, Sundet K. Cognitive Heterogeneity across Schizophrenia and Bipolar Disorder: A Cluster Analysis of Intellectual Trajectories. J Int Neuropsychol Soc. 2020;26:860–72.
Tripathi A, Kar SK, Shukla R. Cognitive Deficits in Schizophrenia: Understanding the Biological Correlates and Remediation Strategies. Clin Psychopharmacol Neurosci. 2018;16:7–17.
Tamminga CA, Clementz BA, Pearlson G, Keshavan M, Gershon ES, Ivleva EI, et al. Biotyping in psychosis: using multiple computational approaches with one data set. Neuropsychopharmacology 2021;46:143–55.
Bishop JR, Zhang L, Lizano P. Inflammation subtypes and translating inflammation-related genetic findings in schizophrenia and related psychoses: A perspective on pathways for treatment stratification and novel therapies. Harv Rev Psychiatry. 2022;30:59–70.
Pape K, Tamouza R, Leboyer M, Zipp F. Immunoneuropsychiatry – novel perspectives on brain disorders. Nat Rev Neurol. 2019;15:317–28.
Morrens M, Overloop C, Coppens V, Loots E, Van Den Noortgate M, Vandenameele S, et al. The relationship between immune and cognitive dysfunction in mood and psychotic disorder: a systematic review and a meta-analysis. Mol Psychiatry. 2022:1–10.
Horváth S, Mirnics K. Immune system disturbances in schizophrenia. Biol Psychiatry. 2014;75:316–23.
Mørch RH, Dieset I, Færden A, Hope S, Aas M, Nerhus M, et al. Inflammatory evidence for the psychosis continuum model. Psychoneuroendocrinology. 2016;67:189–97.
Mullins N, Forstner AJ, O’Connell KS, Coombes B, Coleman JRI, Qiao Z, et al. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nat Genet. 2021;53:817–29.
Ripke S, O’Dushlaine C, Chambert K, Moran JL, Kähler AK, Akterin S, et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet. 2013;45:1150–9.
O’Dushlaine C, Rossin L, Lee PH, Duncan L, Parikshak NN, Newhouse S, et al. Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat Neurosci. 2015;18:199–209.
Yuan N, Chen Y, Xia Y, Dai J, Liu C. Inflammation-related biomarkers in major psychiatric disorders: a cross-disorder assessment of reproducibility and specificity in 43 meta-analyses. Transl Psychiatry. 2019;9:1–13.
Misiak B, Stańczykiewicz B, Łaczmański Ł, Frydecka D. Lipid profile disturbances in antipsychotic-naive patients with first-episode non-affective psychosis: A systematic review and meta-analysis. Schizophr Res. 2017;190:18–27.
Bora E. Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in schizophrenia: a meta-analysis. Psychol Med. 2019;49:1971–9.
Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21:1696–709.
Dieset I, Andreassen OA, Haukvik UK. Somatic Comorbidity in Schizophrenia: Some Possible Biological Mechanisms Across the Life Span. Schizophr Bull. 2016;42:1316–9.
Laursen TM, Munk-Olsen T, Gasse C. Chronic somatic comorbidity and excess mortality due to natural causes in persons with schizophrenia or bipolar affective disorder. PloS One. 2011;6:e24597.
Räuber S, Heming M, Repple J, Ruland T, Kuelby R, Schulte-Mecklenbeck A, et al. Cerebrospinal fluid flow cytometry distinguishes psychosis spectrum disorders from differential diagnoses. Mol Psychiatry. 2021;26:7661–70.
Meyer JH, Cervenka S, Kim M-J, Kreisl WC, Henter ID, Innis RB. Neuroinflammation in psychiatric disorders: PET imaging and promising new targets. Lancet Psychiatry. 2020;7:1064–74.
Kealy J, Greene C, Campbell M. Blood-brain barrier regulation in psychiatric disorders. Neurosci Lett. 2020;726:133664.
van Kesteren CFMG, Gremmels H, de Witte LD, Hol EM, Van Gool AR, Falkai PG, et al. Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies. Transl Psychiatry. 2017;7:e1075.
Penadés R, García-Rizo C, Bioque M, González-Rodríguez A, Cabrera B, Mezquida G, et al. The search for new biomarkers for cognition in schizophrenia. Schizophr Res Cogn. 2015;2:172–8.
Tchessalova D, Posillico CK, Tronson NC. Neuroimmune Activation Drives Multiple Brain States. Front Syst Neurosci. 2018;12:1–9.
De Picker LJ, Morrens M, Chance SA, Boche D. Microglia and Brain Plasticity in Acute Psychosis and Schizophrenia Illness Course: A Meta-Review. Front Psychiatry. 2017;8:238.
Zhao J, Bi W, Xiao S, Lan X, Cheng X, Zhang J, et al. Neuroinflammation induced by lipopolysaccharide causes cognitive impairment in mice. Sci Rep. 2019;9:5790.
Hagi K, Nosaka T, Dickinson D, Lindenmayer JP, Lee J, Friedman J, et al. Association Between Cardiovascular Risk Factors and Cognitive Impairment in People With Schizophrenia: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021;78:510–8.
Miller BJ, Goldsmith DR. Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future Directions. Neuropsychopharmacology 2017;42:299–317.
Miller BJ, Goldsmith DR. Inflammatory biomarkers in schizophrenia: Implications for heterogeneity and neurobiology. Biomark. Neuropsychiatry 2019;1:100006.
Lizano P, Lutz O, Xu Y, Rubin LH, Paskowitz L, Lee AM, et al. Multivariate relationships between peripheral inflammatory marker subtypes and cognitive and brain structural measures in psychosis. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-00914-0.
Zhang L, Lizano P, Guo B, Xu Y, Rubin LH, Hill SK, et al. Inflammation subtypes in psychosis and their relationships with genetic risk for psychiatric and cardiometabolic disorders. Brain Behav Immun – Health. 2022;22:100459.
Fillman SG, Weickert TW, Lenroot RK, Catts SV, Bruggemann JM, Catts VS, et al. Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca’s area volume. Mol Psychiatry. 2016;21:1090–8.
Hoang D, Xu Y, Lutz O, Bannai D, Zeng V, Bishop JR, et al. Inflammatory Subtypes in Antipsychotic-Naïve First-Episode Schizophrenia are Associated with Altered Brain Morphology and Topological Organization. Brain Behav Immun. 2022;100:297–308.
Boerrigter D, Weickert TW, Lenroot R, O’Donnell M, Galletly C, Liu D, et al. Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder. J Neuroinflammation. 2017;14:188.
Mondelli V, Ciufolini S, Belvederi Murri M, Bonaccorso S, Di Forti M, Giordano A, et al. Cortisol and Inflammatory Biomarkers Predict Poor Treatment Response in First Episode Psychosis. Schizophr Bull. 2015;41:1162–70.
Fillman SG, Sinclair D, Fung SJ, Webster MJ, Shannon Weickert C. Markers of inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar disorder. Transl Psychiatry. 2014;4:e365–e365.
Dinga R, Schmaal L, Penninx BWJH, van Tol MJ, Veltman DJ, van Velzen L, et al. Evaluating the evidence for biotypes of depression: Methodological replication and extension of Drysdale et al. (2017). NeuroImage Clin. 2019;22:101796.
Drysdale AT, Grosenick L, Downar J, Dunlop K, Mansouri F, Meng Y, et al. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat Med. 2017;23:28–38.
Zhang T, Tang X, Li H, Woodberry KA, Kline ER, Xu L, et al. Clinical subtypes that predict conversion to psychosis: A canonical correlation analysis study from the ShangHai At Risk for Psychosis program. Aust N. Z J Psychiatry. 2020;54:482–95.
Liu Y, Hayes DN, Nobel A, Marron JS. Statistical Significance of Clustering for High-Dimension, Low–Sample Size Data. J Am Stat Assoc. 2008;103:1281–93.
First MB, Spitzer RL, Gibbon M, Williams JB. Structured Clinical Interview for DSM-IV Axis I Disorders: Patient Edition (SCID-P, Version 2.0). New York State Psychiatric Institute, New York: Biometrics Research Department; 1995.
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–76.
Wallwork RS, Fortgang R, Hashimoto R, Weinberger DR, Dickinson D. Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr Res. 2012;137:246–50.
Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry J Ment Sci. 1978;133:429–35.
Pedersen G, Hagtvet KA, Karterud S. Generalizability studies of the Global Assessment of Functioning–Split version. Compr Psychiatry. 2007;48:88–94.
Wechsler D. Wechsler Abbreviated Scale of Intelligence-Second Edition. 2011. 2011. https://doi.org/10.1037/t15171-000.
Klove H. Clinical Neuropsychology. Med Clin North Am. 1963;47:1647–58.
Wechsler D. Wechsler Adult Intelligence Scale-Third Edition. 1997. 1997. https://doi.org/10.1037/t49755-000.
Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165:203–13.
Mohn C, Sundet K, Rund BR. The Norwegian standardization of the MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) Consensus Cognitive Battery. J Clin Exp Neuropsychol. 2012;34:667–77.
Delis DC, Kaplan E, Kramer JH. Delis-Kaplan Executive Function System. 2001. 2001. https://doi.org/10.1037/t15082-000.
Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test–Second Edition. 1987. 1987. https://doi.org/10.1037/t15072-000.
Benedict RHB, Schretlen D, Groninger L, Brandt J. Hopkins Verbal Learning Test – Revised: Normative Data and Analysis of Inter-Form and Test-Retest Reliability. Clin Neuropsychol. 1998;12:43–55.
Andreou D, Steen NE, Jørgensen KN, Smelror RE, Wedervang-Resell K, Nerland S, et al. Lower circulating neuron-specific enolase concentrations in adults and adolescents with severe mental illness. Psychol Med. 2021:1–10. https://doi.org/10.1017/S0033291721003056.
Engh JA, Ueland T, Agartz I, Andreou D, Aukrust P, Boye B, et al. Plasma Levels of the Cytokines B Cell-Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL) in Schizophrenia, Bipolar, and Major Depressive Disorder: A Cross Sectional, Multisite Study. Schizophr Bull. 2021;48:37–46.
Szabo A, O’Connell KS, Ueland T, Sheikh MA, Agartz I, Andreou D, et al. Increased circulating IL-18 levels in severe mental disorders indicate systemic inflammasome activation. Brain Behav Immun. 2022;99:299–306.
Hjell G, Szabo A, Mørch-Johnsen L, Holst R, Tesli N, Bell C, et al. Interleukin-18 signaling system links to agitation in severe mental disorders. Psychoneuroendocrinology 2022;140:105721.
Elkjaer Greenwood Ormerod MB, Ueland T, Frogner Werner MC, Hjell G, Rødevand L, Sæther LS, et al. Composite immune marker scores associated with severe mental disorders and illness course. Brain Behav Immun – Health. 2022;24:100483.
Hotelling H. Relations Between Two Sets of Variates. Biometrika 1936;28:321–77.
Luperdi SC, Correa-Ghisays P, Vila-Francés J, Selva-Vera G, Salazar-Fraile J, Cardoner N, et al. Is processing speed a valid neurocognitive endophenotype in bipolar disorder? Evidence from a longitudinal, family study. J Psychiatr Res. 2021;141:241–7.
Mathias SR, Knowles EEM, Barrett J, Leach O, Buccheri S, Beetham T, et al. The Processing-Speed Impairment in Psychosis Is More Than Just Accelerated Aging. Schizophr Bull. 2017;43:814–23.
Vöhringer PA, Barroilhet SA, Amerio A, Reale ML, Alvear K, Vergne D, et al. Cognitive Impairment in Bipolar Disorder and Schizophrenia: A Systematic Review. Front Psychiatry. 2013;4:87.
Schaefer J, Giangrande E, Weinberger DR, Dickinson D. The global cognitive impairment in schizophrenia: Consistent over decades and around the world. Schizophr Res. 2013;150:42–50.
Ojeda N, Peña J, Schretlen DJ, Sánchez P, Aretouli E, Elizagárate E, et al. Hierarchical structure of the cognitive processes in schizophrenia: the fundamental role of processing speed. Schizophr Res. 2012;135:72–78.
Dickinson D, Ramsey ME, Gold JM. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry. 2007;64:532–42.
Carrión RE, Walder DJ, Auther AM, McLaughlin D, Zyla HO, Adelsheim S, et al. From the psychosis prodrome to the first-episode of psychosis: No evidence of a cognitive decline. J Psychiatr Res. 2018;96:231–8.
Glahn DC, Almasy L, Blangero J, Burk GM, Estrada J, Peralta JM, et al. Adjudicating neurocognitive endophenotypes for schizophrenia. Am J Med Genet Part B Neuropsychiatr Genet Publ Int Soc Psychiatr Genet. 2007;144B:242–9.
Alboni S, Cervia D, Sugama S, Conti B. Interleukin 18 in the CNS. J Neuroinflammation. 2010;7:1–12.
Cheon SY, Kim J, Kim SY, Kim EJ, Koo B-N. Inflammasome and Cognitive Symptoms in Human Diseases: Biological Evidence from Experimental Research. Int J Mol Sci. 2020;21:1103.
Gris D, Ye Z, Iocca HA, Wen H, Craven RR, Gris P, et al. NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. J Immunol Balt Md. 1950;2010:974–81.
Gordon R, Albornoz EA, Christie DC, Langley MR, Kumar V, Mantovani S, et al. Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice. Sci Transl Med. 2018;10:eaah4066.
Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol. 2008;9:857–65.
Liang T, Zhang Y, Wu S, Chen Q, Wang L. The Role of NLRP3 Inflammasome in Alzheimer’s Disease and Potential Therapeutic Targets. Front Pharmacol. 2022;13:1–21.
Schluesener H, Meyermann R. Neutrophilic defensins penetrate the blood-brain barrier. J Neurosci Res. 1995;42:718–23.
Williams WM, Castellani RJ, Weinberg A, Perry G, Smith MA. Do β-Defensins and Other Antimicrobial Peptides Play a Role in Neuroimmune Function and Neurodegeneration? Sci World J 2012;2012:905785.
Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J, et al. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science. 1999;286:525–8.
Niyonsaba F, Ushio H, Nagaoka I, Okumura K, Ogawa H. The human beta-defensins (-1, -2, -3, -4) and cathelicidin LL-37 induce IL-18 secretion through p38 and ERK MAPK activation in primary human keratinocytes. J Immunol Balt Md 1950. 2005;175:1776–84.
Yang R, Yang E, Shen L, Modlin RL, Shen H, Chen ZW. IL-12+IL-18 Cosignaling in Human Macrophages and Lung Epithelial Cells Activates Cathelicidin and Autophagy, Inhibiting Intracellular Mycobacterial Growth. J Immunol Balt Md. 1950;2018:2405–17.
Sheikh MA, O’Connell KS, Lekva T, Szabo A, Akkouh IA, Osete JR, et al. Systemic cell-adhesion molecules (CAM) in severe mental illness-potential role of intracellular CAM-1 in linking peripheral and neuro-inflammation. Biol Psychiatry. 2022;93:187–96.
Dietrich J-B. The adhesion molecule ICAM-1 and its regulation in relation with the blood-brain barrier. J Neuroimmunol. 2002;128:58–68.
Kong D-H, Kim YK, Kim MR, Jang JH, Lee S. Emerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer. Int J Mol Sci. 2018;19:E1057.
Hummel V, Kallmann BA, Wagner S, Füller T, Bayas A, Tonn JC, et al. Production of MMPs in human cerebral endothelial cells and their role in shedding adhesion molecules. J Neuropathol Exp Neurol. 2001;60:320–7.
Kallmann BA, Hummel V, Lindenlaub T, Ruprecht K, Toyka KV, Rieckmann P. Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1. Brain 2000;123:687–97.
Morel JC, Park CC, Woods JM, Koch AE. A novel role for interleukin-18 in adhesion molecule induction through NF kappa B and phosphatidylinositol (PI) 3-kinase-dependent signal transduction pathways. J Biol Chem. 2001;276:37069–75.
Stenfors CUD, Jonsdottir IH, Magnusson Hanson LL, Theorell T. Associations between systemic pro-inflammatory markers, cognitive function and cognitive complaints in a population-based sample of working adults. J Psychosom Res. 2017;96:49–59.
Beydoun MA, Dore GA, Canas J-A, Liang H, Beydoun HA, Evans MK, et al. Systemic Inflammation Is Associated With Longitudinal Changes in Cognitive Performance Among Urban Adults. Front Aging Neurosci. 2018;10:1-12.
Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25:1822–32.
Wedervang-Resell K, Ueland T, Aukrust P, Friis S, Holven KB, H. Johannessen C, et al. Reduced levels of circulating adhesion molecules in adolescents with early-onset psychosis. Npj Schizophr. 2020;6:1–8.
Reponen EJ, Dieset I, Tesli M, Mørch RH, Aas M, Vedal TSJ, et al. Atherogenic lipid ratios related to myeloperoxidase and C-reactive protein levels in psychotic disorders. Front Psychiatry 2020;11:672.
